A reagent for use in the measurement of hemoglobins by liquid chromatography, the reagent comprising a nonionic surfactant selected from the group consisting of:

(i) polyoxyethylene (10) decyl ether; (ii) polyoxyethylene (6) 2-ethylhexyl ether; (iii) polyoxyethylene (9) isodecyl ether; (iv) polyoxyethylene (10) nonyl ether; (v) polyoxyethylene (16) isostearyl ether; (vi) polyoxyethylene (20) behenyl ether; and (vii) polyoxyethylene (20) polyoxypropylene (6) decyltetradecyl ether.

Methods of purifying adenovirus that can be performed on a large scale. The methods purify adenovirus from an adenovirus-containing sample comprising or derived from a host cell population by clarifying the sample, wherein clarification comprises depth filtration followed by microfiltration; processing the clarified sample by anion exchange chromatography; and processing the anion exchange product by tangential flow filtration (TFF) to provide a TFF product.

A method for making a caffeoylquinic composition from a botanical source is disclosed. The method may include chromatographing an extract of biomass on an ion exchange stationary phase and obtaining an eluent comprising a caffeoylquinic composition. The biomass may be Stevia or yerba mate, for example. The caffeoylquinic composition includes one or more of monocaffeoylquinic acid, dicaffeoylquinic acid, and salts of the foregoing.

A new column-based purification system and approach are described for rapid separation and purification of the alpha-emitting therapeutic radioisotope .sup.211At from dissolved cyclotron targets that provide highly reproducible product results with excellent .sup.211At species distributions and high antibody labeling yields compared with prior art manual extraction results of the prior art that can be expected to enable enhanced production of purified .sup.211At isotope products suitable for therapeutic medical applications such as treatment of cancer in human patients.

A new column-based purification system and approach are described for rapid separation and purification of the alpha-emitting therapeutic radioisotope .sup.211At from dissolved cyclotron targets that provide highly reproducible product results with excellent .sup.211At species distributions and high antibody labeling yields compared with prior art manual extraction results of the prior art that can be expected to enable enhanced production of purified .sup.211At isotope products suitable for therapeutic medical applications such as treatment of cancer in human patients.

A method of producing protein products including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins from plasma includes steps of: (1) adding a salt to the blood product to produce a first intermediate, wherein the salt comprises between 11-13 wt % of the first intermediate; (2) separating the first intermediate to produce a first supernatant and a first paste; (3) adding a salt to the first intermediate to produce a second intermediate, wherein the salt comprises between 21-23 wt % of the second intermediate; (4) separating the second intermediate to produce a second supernatant and a second paste; (5) separating a third intermediate from the second supernatant by affinity chromatography; and (6) separating the third intermediate by ion exchange chromatography to produce an eluate containing the protein product. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields.

A method of producing protein products including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins from plasma includes steps of: (1) adding a salt to the blood product to produce a first intermediate, wherein the salt comprises between 11-13 wt % of the first intermediate; (2) separating the first intermediate to produce a first supernatant and a first paste; (3) adding a salt to the first intermediate to produce a second intermediate, wherein the salt comprises between 21-23 wt % of the second intermediate; (4) separating the second intermediate to produce a second supernatant and a second paste; (5) separating a third intermediate from the second supernatant by affinity chromatography; and (6) separating the third intermediate by ion exchange chromatography to produce an eluate containing the protein product. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields.

Disclosed herein is a method and apparatus that uses a brine from a well that is used to both generate electricity and recover valuable minerals present in the brine. The method and apparatus uses a hydrophobic membrane to separate water vapor from the brine to concentrate the brine that is then used to recover the minerals.

Disclosed herein is a method and apparatus that uses a brine from a well that is used to both generate electricity and recover valuable minerals present in the brine. The method and apparatus uses a hydrophobic membrane to separate water vapor from the brine to concentrate the brine that is then used to recover the minerals.

A chromatography analysis apparatus (30) comprises: a fractionation device (32) for receiving a sample, the fractionation device (32) defining a sample flow path that includes a guard column; and a fractionation output analyser (34), wherein a fractionation output of the guard column is provided to an input of the fractionation output analyser (34) for enabling subsequent analysis of the fractionation output by the fractionation output analyser (34).